A NEW APPROACH
TO OBESITY AND
TYPE 2 DIABETES
WE ARE FOCUSED ON TRANSFORMING THE TREATMENT OF OBESITY & TYPE 2 DIABETES
Obesity and type 2 diabetes (T2D) are progressive metabolic diseases. Traditional treatments have focused on managing the symptoms of these diseases, like body weight and blood sugar. But treating the symptoms alone does not prevent the disease from getting steadily worse. Because obesity and T2D keep progressing, many people require lifelong therapy and potentially even more medications to control their disease. We believe that new approaches are needed to address obesity and T2D. Our goal is to treat the root cause, which we believe is in the gut (the duodenum).
Enrolling Today
If you have type 2 diabetes, you could benefit from a clinical research study evaluating a non-drug procedure that may help improve blood sugar and body weight without increasing medicines or insulin. Revitalize 1 is a pivotal clinical study of an investigational procedure called Revita and is expected to enroll more than 300 people with T2D across 35 procedure centers in the United States and Europe.
Learn More about Revitalize 1
Enrolling Soon
If you have obesity, you could benefit from a clinical research study evaluating a non-drug procedure that may help you maintain body weight loss after stopping GLP-1 based drug therapy. Remain-1 is a pivotal clinical study that is expected to begin enrolling in the second half of 2024 across the United States. If you are interested in participating in a study that will evaluate the potential for Revita to help maintain weight loss (in conjunction with diet and exercise) after stopping GLP-1 based drugs, Remain-1 may be right for you.
Learn More about Remain 1